Neurodiagnostics Market: Market Size & Forecast 2026

The global neurodiagnostics market covers a broad portfolio of technologies used to evaluate the structure and function of the nervous system, including imaging systems, electrophysiology devices, and in-vitro diagnostic reagents. In 2026, the market is valued at approximately $9.7 billion, with projections extending to between $13.8 billion and $18.1 billion by 2030-2035 depending on the scope of analysis. Reagents and consumables represent the largest product segment, accounting for roughly 55% of the market, reflecting recurring procurement cycles across hospital laboratories and reference facilities.

• •Market valued at approximately $9.7 billion in 2026
• •Reagents and consumables hold roughly 55% market share
• •Long-term projections range from $13.8 billion to $18.1 billion by 2030-2035

The market is primarily fueled by the rising global burden of neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and stroke, alongside demographic aging in major developed and developing economies. Improvements in neuroimaging resolution, biomarker specificity, and digital data processing are enabling earlier and more accurate diagnosis, effectively expanding the treatable patient population. Expanding diagnostic infrastructure, growing healthcare expenditure, and increased government and institutional focus on neurological care collectively sustain robust demand across the forecast horizon.

• •Rising global prevalence of neurodegenerative and cerebrovascular diseases
• •Technological improvements in imaging resolution and biomarker sensitivity
• •Expanding diagnostic infrastructure in emerging healthcare markets

By product type, the market is dominated by reagents and consumables, which benefit from recurring purchase requirements, while imaging devices and electrophysiology systems represent higher-value, longer-replacement-cycle segments. Neuroimaging technologies, including computed tomography and magnetic resonance imaging, form a foundational category, with neurological biomarker-based diagnostics emerging as a high-growth sub-market. Geographically, North America and Europe account for the largest revenue shares due to advanced healthcare systems and high diagnostic penetration, whereas Asia-Pacific is the fastest-growing region driven by improving access, rising disease awareness, and healthcare infrastructure investment.

• •Reagents and consumables represent approximately 55% of total market value
• •Neuroimaging modalities form a major technology segment alongside growing biomarker-based diagnostics
• •North America and Europe lead in share; Asia-Pacific is the fastest-growing regional market

Who are the notable companies in the industry?

The competitive landscape exhibits moderate fragmentation, shaped by a mix of large diversified healthcare manufacturers and smaller specialized producers with deep expertise in specific neurodiagnostic modalities. Siemens Healthineers, GE Healthcare, Koninklijke Philips, Canon, and FUJIFILM bring broad imaging and monitoring capabilities spanning MRI, CT, ultrasound, and digital radiography, while Thermo Fisher Scientific and Roche leverage extensive reagent portfolios and in-vitro diagnostic platforms. Natus Medical differentiates itself through focused electrophysiology and neonatal neurology solutions. Integrated producers compete on cross-selling breadth, bundling hardware, software, and service contracts, whereas specialty players concentrate on biomarker assay development and targeted imaging enhancements. Manufacturing and R&D capacity remains concentrated in regions with mature regulatory ecosystems and advanced industrial infrastructure, with meaningful activity centered in North America, Western Europe, and East Asia.

• •Moderate fragmentation with both diversified manufacturers and specialized producers coexisting
• •Integrated players operate across multiple product and technology categories; specialists focus on narrower segments
• •Manufacturing and R&D capacity concentrated in North America, Europe, and East Asia

What are the recent trends and outlook?

Key trends include the accelerating adoption of digital analysis platforms and artificial intelligence-assisted tools that enhance diagnostic accuracy, reduce interpretation time, and improve clinical workflow efficiency. A broader shift toward biomarker-driven and minimally invasive diagnostic approaches is reducing sole reliance on traditional structural imaging, while the integration of genomic and molecular profiling with neurodiagnostic workflows is paving the way for more personalized neurological care. The market is positioned for consistent expansion through the early 2030s, supported by continued clinical adoption, pipeline innovation, and widening geographic reach as emerging markets invest in neurological diagnostic capacity.

• •Growing integration of AI-assisted image and electrophysiology data analysis
• •Shift toward biomarker-based and molecular diagnostic approaches
• •Convergence with genomic profiling and precision medicine platforms